The protocol doubles the dose, twice. The initial dose is already much higher than the usual starting dose for oncological drugs, then that gets doubled and doubled again. Mice showed efficacy, albeit low efficacy, at very low dosages. Efficacy increased with each dose increase. I think we see efficacy in the second round, but the third round will confirm it. I won't be surprised by efficacy in the final analysis of the first round, but that will be at least 1 to 3 months away. By then Kevetrin will have completed the 2 nd round and possibly the 3rd.